Letybo (LetibotulinumtoxinA)
FDA-approved next-gen botulinum toxin with lower cost & side effects
이 치료에 대해
Letybo (LetibotulinumtoxinA-wlbg) is a next-generation botulinum toxin type A developed by Hugel (South Korea), FDA-approved in February 2024. Chemically distinct from Botox (onabotulinumtoxinA), it's indicated for moderate-to-severe glabellar lines.
Phase III trials showed eyelid ptosis rate of only 0.5% (roughly 1/3 of Botox), with no neutralizing antibodies detected. Per-unit cost is 10-20% lower than Botox, making it a cost-effective alternative.
작용 기전
Botulinum toxin type A cleaves SNARE proteins at the neuromuscular junction, inhibiting acetylcholine release for temporary muscle relaxation. Letybo uses a proprietary purification process yielding a 900kDa formulation with high purity and stability.
적응증
기대 효과
Onset in 3-7 days, peak at 14 days. Duration 12-16 weeks. Ptosis risk ~1/3 of Botox (0.5%). Most common side effect: headache (2%).
임상 근거
위험 및 부작용
Headache (2%), transient injection site reactions. Ptosis risk 0.5%. Rare brow asymmetry. Overcorrection may cause unnatural expression. Contraindicated in pregnancy/breastfeeding.